A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
about
Narrative review of the safety and efficacy of marijuana for the treatment of commonly state-approved medical and psychiatric disordersThe therapeutic potential of cannabis and cannabinoidsEvidence for the efficacy and effectiveness of THC-CBD oromucosal spray in symptom management of patients with spasticity due to multiple sclerosisNeural Plasticity in Multiple Sclerosis: The Functional and Molecular BackgroundCurrent Therapeutic Cannabis Controversies and Clinical Trial Design IssuesMarijuana Legalization: Impact on Physicians and Public HealthPharmacological management of spasticity in multiple sclerosis: Systematic review and consensus paper.Long-Term Data of Efficacy, Safety, and Tolerability in a Real-Life Setting of THC/CBD Oromucosal Spray-Treated Multiple Sclerosis Patients.Evolution of multiple sclerosis spasticity-associated symptoms: latest data.Linguistic and psychometric validation of the MSSS-88 questionnaire for patients with multiple sclerosis and spasticity in GermanyThe pharmacologic and clinical effects of medical cannabis.Therapeutic potential of cannabinoid medicines.Systematic review: efficacy and safety of medical marijuana in selected neurologic disorders: report of the Guideline Development Subcommittee of the American Academy of Neurology.Medical marijuana in neurology.A placebo-controlled, parallel-group, randomized withdrawal study of subjects with symptoms of spasticity due to multiple sclerosis who are receiving long-term Sativex® (nabiximols).Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity.CB1 receptor affects cortical plasticity and response to physiotherapy in multiple sclerosis.Cost-effectiveness of Sativex in multiple sclerosis spasticity: new data and application to Italy.Evaluating Sativex® in Neuropathic Pain Management: A Clinical and Neurophysiological Assessment in Multiple Sclerosis.Clinical Use of Cannabinoids for Symptom Control in Multiple Sclerosis.Evaluation of the Effects of Sativex (THC BDS: CBD BDS) on Inhibition of Spasticity in a Chronic Relapsing Experimental Allergic Autoimmune Encephalomyelitis: A Model of Multiple Sclerosis.Effects of fixed or self-titrated dosages of Sativex on cannabis withdrawal and cravings.Effect of dronabinol on progression in progressive multiple sclerosis (CUPID): a randomised, placebo-controlled trial.Efficacy and safety of cannabinoid oromucosal spray for multiple sclerosis spasticityOral fluid and plasma cannabinoid ratios after around-the-clock controlled oral Δ(9)-tetrahydrocannabinol administration.An observational postmarketing safety registry of patients in the UK, Germany, and Switzerland who have been prescribed Sativex® (THC:CBD, nabiximols) oromucosal spray.Marijuana Compounds: A Nonconventional Approach to Parkinson's Disease Therapy.In vivo Evidence for Therapeutic Properties of Cannabidiol (CBD) for Alzheimer's Disease.Clinical efficacy and effectiveness of Sativex, a combined cannabinoid medicine, in multiple sclerosis-related spasticity.Evaluation of the safety and tolerability profile of Sativex: is it reassuring enough?Nabiximols in the treatment of spasticity, pain and urinary symptoms due to multiple sclerosis.Endocannabinoid system modulator use in everyday clinical practice in the UK and Spain.A new multiple sclerosis spasticity treatment option: effect in everyday clinical practice and cost-effectiveness in Germany.Pharmacokinetic evaluation of nabiximols for the treatment of multiple sclerosis pain.Multiple sclerosis spasticity management--key publications.Advances in the management of multiple sclerosis spasticity: experiences from recent studies and everyday clinical practice.Clinical case reviews in multiple sclerosis spasticity: experiences from around Europe.Delta-9-tetrahydrocannabinol/cannabidiol (Sativex®): a review of its use in patients with moderate to severe spasticity due to multiple sclerosis.Impact of Sativex(®) on quality of life and activities of daily living in patients with multiple sclerosis spasticity.Evaluation of the tolerability and efficacy of Sativex in multiple sclerosis.
P2860
Q22299116-B52EF6BE-DAD7-4773-A2AA-20AB73C5957EQ24600806-008CCED8-D676-4580-B8A1-F1B744149AC3Q26770823-64A16201-4226-4998-B987-97C443BF8D46Q26801046-BAA29003-C452-4BFE-80CD-51B00416BD39Q28071794-42DDFA85-9C12-4B54-99DB-CC2D6D8503B6Q28082785-AC63C3FF-9516-4E68-B372-62818474A617Q30250250-FEC5EBF3-235E-459F-B7F4-9C2B32863673Q31028236-1F1851E5-D4F2-41CF-BDAB-6FE12780CDBBQ31144052-B1D07DB7-16AD-4C9C-B790-FD9E8ADD9EC8Q34105894-ADC79E5B-073A-4C20-BAD0-EC5781F23330Q34326515-0F289DA7-A0B2-4A35-AB19-16711ACC5B9AQ34368715-C3E48FB2-C5A2-4145-A2AE-E916853051D2Q34417710-511AA908-E13C-4225-8313-4F7E2F4D88F8Q34449698-AF6584F6-27B7-4F58-9C9E-B889D5926196Q34631934-450A8A4F-D8AC-498B-9246-BA62D4F26F69Q34642592-91D1CE21-6FB5-4A2A-BF69-0A9D0F0A2C71Q34714518-081C4B90-29D7-44E1-9C69-019AE34C472FQ35577414-44877E26-2C63-460C-91DA-B5820E3B01D5Q35893522-0F27A917-2CC6-4B4C-8266-490F2AA6E9B1Q36157623-CB4AC19A-06FC-48B9-B457-B175152648CDQ36178329-D0283A49-8A4C-4BA4-AE67-C7178C7C8DD8Q36932158-97DBA42A-EFF2-488A-B987-1C507ACFA6CBQ37098220-00519793-48C3-4EB7-A1EE-E16B30826E5BQ37235845-D47B836C-5927-46CA-9833-56F2EA2902E8Q37331681-053E0D3A-3D03-4AF2-A146-C38D1222BE72Q37420740-2DC00893-1D76-49BF-8996-2BCB023CEB38Q37512670-47933FD2-0732-49D9-A07F-7A89D0C8DDBFQ37622090-33396D4E-2F12-4759-981F-560D1672FD89Q38003185-366374C3-B0EF-4752-9C90-54ACBBFB1221Q38003186-9DBC468F-48DB-4D81-AB5D-E274942E9749Q38041231-1390553E-BDE3-495C-88F4-3A2B835D1C5DQ38078053-46A4C5E5-28D4-4B6A-A417-7D94994EDB47Q38078054-FBDF736E-84C4-47AB-B380-05D7DE9278ABQ38102053-D06FAA89-F8D1-4633-93BE-5177D55E0C8EQ38167396-B3254E8C-38BC-4B8D-A2D2-2B29C1A417DBQ38167397-87DA1EC8-A601-4215-A609-2589F4BFE231Q38167399-AAF8DA60-3AA8-448D-8EC9-290C8EFC1751Q38199658-F77BED57-2FA3-4F73-9D61-8213ABC6E681Q38256059-9BCE0913-5072-4306-848B-E0264DCDB097Q38261541-5AFA88C0-CE60-4DB2-AC4D-555178B246C3
P2860
A randomized, double-blind, placebo-controlled, parallel-group, enriched-design study of nabiximols* (Sativex(®) ), as add-on therapy, in subjects with refractory spasticity caused by multiple sclerosis.
description
2011 nî lūn-bûn
@nan
2011 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2011 թվականի մարտին հրատարակված գիտական հոդված
@hy
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
name
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@ast
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@en
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@nl
type
label
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@ast
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@en
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@nl
prefLabel
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@ast
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@en
A randomized, double-blind, pl ...... caused by multiple sclerosis.
@nl
P2093
P50
P1476
A randomized, double-blind, pl ...... y caused by multiple sclerosis
@en
P2093
C Pozzilli
I Novakova
O Zapletalova
P304
P356
10.1111/J.1468-1331.2010.03328.X
P577
2011-03-01T00:00:00Z